Phase 2 N=35 A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer
Colorectal Cancer
Primary: Durable Clinical Benefit — 3; 32 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=12 Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)
High Tumor Mutation Burden · High TMB (Tumor Mutation Burden) · MSS (Microsatellite Stable)
Primary: Objective Response Rate (ORR) in Patients With MSI (Microsatellite Unstable)-Negative Solid Tumor Malignancies With a Mutator Phenotype — 5 Participants
Phase 2 N=72 Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Colorectal Neoplasms · Microsatellite Instability
Primary: Overall Response Rate (ORR) — 0 % of participants
Phase 2 N=33 Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Phase 2 N=4 M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
Colon Adenocarcinoma · High-Frequency Microsatellite Instability · Metastatic Malignant Solid Neoplasm
Primary: Percentage of Circulating DNA Clearance — 0 percentage of DNA cleared
Phase 2 N=76 METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
Colorectal Cancer Metastatic
Primary: Primary - Progression-free Survival (PFS) — 9.2; 9.2 Months of progression-free survival
N/A N=239 Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer
Colorectal Cancer · Hereditary Non-polyposis Colon Cancer
Primary: Impact of Standard Informed Consent vs CD-ROM Educational Intervention on Knowledge About Microsatellite Instability (MSI) Testing — 4.07; 4.17 units on a scale
Phase 2 N=21 Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation
MSS · RAS-mutant Colorectal Cancer
Primary: Phase 1b: Number of Participants With Dose-Limiting Toxicities (DLT) — 1; 2 Participants
Phase 2 N=113 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
MSI Positive Colorectal Cancer · MSI Negative Colorectal Cancer · MSI Positive Non-Colorectal Cancers
Primary: Immune-related Progression Free Survival (irPFS) at 20 Weeks in MSI Positive and Negative Colorectal Adenocarcinoma Participants Using Immune Related Response Criteria…
Phase 1 N=20 Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC
Metastatic Colorectal Cancer · MSS
Primary: Feasibility Rate of a Combined Therapy — 18 Participants
N/A N=150 Ploidy and Stroma in Early Rectal Cancer
Rectal Cancer
Primary: Correlation Between Ploidy Status With Local Recurrence of Cancer — 3; 31; 14; 92 Participants
Phase 2 N=29 Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial
Stage IV Non-Small Cell Lung Cancer
Primary: Progression Free Survival — 3.5; 9.7 months — p=.01
Phase 2 N=59 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Microsatellite Stable (MSS) Colorectal Adenocarcinomas · Colorectal Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 1; 2 Participants
N/A N=250 Ancillary Study of Methylation Biomarkers in a Randomized Controlled Trial of a Personalized Prevention of Colorectal Cancer
Colorectal Cancer
Primary: Changes of Cytosine Modification in TMPRSS2 (5-mC at cg16371860) by Magnesium Treatment Versus Placebo — 0.007; -0.001; 0.012; -0.002 units on CpG sites — p=<0.05
Phase 3 N=307 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Colorectal Carcinoma
Primary: Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor — 16.5; 8.2 Months — p=0.0001
Phase 2 N=33 Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
Colorectal Cancer Metastatic
Primary: Overall Objective Response Rate (ORR) of Dual Immune Checkpoint Blockade by RECIST 1.1 — 9.52 percentage of participants
Phase 2 N=29 Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
Malignant Neoplasms of Digestive Organs · Colorectal Cancer · Colon Cancer
Primary: Immune-related Best Overall Response Rate. — 1 Participants
N/A N=384 Post-resection Treatment of Large Colon Polyps
Recurrence
Primary: Recurrence — 10; 5; 24 Polyps
Phase 2 N=35 Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
Locally Advanced Malignant Solid Neoplasm
Primary: Pathological Complete Response (pCR). — 67 Percentage
Phase 2 N=11 TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Colorectal Cancer
Primary: Overall Response Rate — 0; 0; 5; 4 Participants
Phase 2 N=135 Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma
Rectal Carcinoma
Primary: Rate of Tumor Downstaging Compared With Historical Controls. — 64.4; 64.5 percentage of participants
Phase 2 N=6 MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
Adenocarcinoma of the Colon · Adenocarcinoma of the Rectum
Primary: Progression Free Survival (PFS) — 0; 0 Participants
Phase 2 N=33 Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
Colorectal Cancer
Primary: Tumour Response — 0; 0 Percentage of Participants
Phase 2 N=124 Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Colorectal Carcinoma
Primary: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor — 32.8; 34.9 Percentage of participants
N/A N=5,696 Screening More Patients for Colorectal Cancer Through Adapting and Refining Targeted Evidence-Based Interventions in Rural Settings, SMARTER CRC
Colorectal Carcinoma
Primary: Likelihood of Any Colorectal Cancer (CRC) Screening (for Study-eligible Patients) — 11.8; 4.5 Percentage of participants
Phase 2 N=18 A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC
Refractory Metastatic Colorectal Cancer
Primary: Immune-Related Overall Response Rate (irORR) — 0 percentage of participants
Phase 2 N=25 A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
Colorectal Cancer
Primary: RXC004 Monotherapy (Arm A): Disease Control Rate (DCR) Using Each Patient's Best Overall Response (BOR) According to Response Evaluation Criteria in Solid Tumours…
Phase 2 N=1,044 A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 9.99; 11.60; 7.13; 7.36 months — p== 0.872
Phase 2 N=221 Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Colorectal Cancer
Primary: Progression Free Survival — 11.4; 5.9 Months — p=0.004
Phase 2 N=29 Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
Colorectal Adenocarcinoma · Metastatic Microsatellite Stable Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Overall Response Rate (ORR) — 2; 16 Participants